Rilonacept is IL-1 receptor fusion protein consisting of the Fc portion of human IgG1 and the human IL-1 receptor.
Target
IL1 [HSA:3552 3553] [KO:K04383 K04519]
Pathway
hsa04010
MAPK signaling pathway
hsa04060
Cytokine-cytokine receptor interaction
hsa04064
NF-kappa B signaling pathway
hsa04620
Toll-like receptor signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AC Interleukin inhibitors
L04AC04 Rilonacept
D06635 Rilonacept (USAN/INN) <US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
Interleukin Blockers
Rilonacept
D06635 Rilonacept (USAN/INN)
Drug groups [BR:br08330]
Immunological agent
DG02019 Interleukin inhibitor
D06635 Rilonacept
Drug classes [BR:br08332]
Immunological agent
DG02019 Interleukin inhibitor
D06635 Rilonacept
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Interleukins
IL1
D06635 Rilonacept (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06635
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06635